Time to Treatment and Patient Outcomes among TB Suspects Screened by a Single Point-of-Care Xpert MTB/RIF at a Primary Care Clinic in Johannesburg, South Africa

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Hanrahan, Colleen F ^a   Selibas, Katerina ^b   Deery, Christopher B ^b   Dansey, Heather ^c   Clouse, Kate ^a,b   Bassett, Jean ^c   Scott, Lesley ^b   Stevens, Wendy ^b,d   Sanne, Ian ^b   van Rie, Annelies ^a  

^a IL   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c Witkoppen Health and Welfare Centre   (South Africa)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASSAY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC KIT; FEMALE; HOSPITAL INFORMATION SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CULTURE; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MORTALITY; SCREENING TEST; SOUTH AFRICA; SPUTUM SMEAR; STANDARD; THORAX RADIOGRAPHY; TIME TO TREATMENT; TREATMENT OUTCOME; TUBERCULOSIS; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; PRIMARY HEALTH CARE; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; VIROLOGY;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TUBERCULOSTATIC AGENT;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; COINFECTION; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; POINT-OF-CARE SYSTEMS; PRIMARY HEALTH CARE; SOUTH AFRICA; SPUTUM; TIME-TO-TREATMENT; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84878806288     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065421     Document Type: Article

References (20)

1. WHO (2011) Global Tuberculosis Control. Geneva.
2. Blakemore R, Nabeta P, Davidow AL, Vadwai V, Tahirli R, et al. (2011) A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. Am J Respir Crit Care Med 184: 1076-1084.
3. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363: 1005-1015.
4. Chang K, Lu W, Wang J, Zhang K, Jia S, et al. (2012) Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect 64: 580-588.
5. WHO (2011) Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva, Switzerland.
6. Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, et al. (2012) The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 7: e36966.
7. Banada PP, Sivasubramani SK, Blakemore R, Boehme C, Perkins MD, et al. (2010) Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. J Clin Microbiol 48: 3551-3557.
8. Clouse K, Page-Shipp L, Dansey H, Moatlhodi B, Scott L, et al. (2012) Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J 102: 805-807.
9. Schnippel K, Meyer-Rath G, Long L, MacLeod W, Sanne I, et al. (2012) Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health 17: 1142-1151.
10. Lawn SD, Kerkhoff AD, Wood R (2012) Location of Xpert(R) MTB/RIF in centralised laboratories in South Africa undermines potential impact. Int J Tuberc Lung Dis 16: 701; author reply 702.
11. Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, et al. (2011) Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 184: 132-140.
12. Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, et al. (2011) Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 8: e1001061.
13. Lawn SD, Kerkhoff AD, Vogt M, Ghebrekristos Y, Whitelaw A, et al. (2012) Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis 54: 1071-1079.
14. Theron G, Pooran A, Peter J, van Zyl-Smit R, Kumar Mishra H, et al. (2012) Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting? Eur Respir J 40: 161-168.
15. Zou G, (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159: 702-706.
16. Harries AD, (1997) Tuberculosis in Africa: clinical presentation and management. Pharmacol Ther 73: 1-50.
17. Lawn SD, Kerkhoff AD, Vogt M, Wood R, (2012) Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 12: 201-209.
18. Yoon C, Cattamanchi A, Davis JL, Worodria W, den Boon S, et al. (2012) Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLOS ONE 7: e48599.
19. Straetemans M, Glaziou P, Bierrenbach AL, Sismanidis C, van der Werf MJ, (2011) Assessing tuberculosis case fatality ratio: a meta-analysis. PLoS One 6: e20755.
20. Kufa T, Mngomezulu V, Charalambous S, Hanifa Y, Fielding K, et al. (2012) Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control. J Acquir Immune Defic Syndr 60: e22-28.